Solid Biosciences
SLDB
156 hedge funds and large institutions have $1.14B invested in Solid Biosciences in 2026 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 60 increasing their positions, 39 reducing their positions, and 26 closing their positions.
1,197% more call options, than puts
Call options by funds: $1.73M | Put options by funds: $133K
59% more capital invested
Capital invested by funds: $717M → $1.14B (+$427M)
54% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 39
38% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 26
15.02% more ownership
Funds ownership: 101.34% → 116.35% (+15%)
4% more funds holding
Funds holding: 150 → 156 (+6)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$29.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$23.1M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$20.4M |
| 5 |
BlackRock
New York
|
+$15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$21.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.2M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$8.39M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$6.98M |
| 5 |
ABG
Ally Bridge Group
New York
|
-$3.87M |
SLDB Hedge Fund Activity: Q2 2026 in Review
156 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q2 2026, worth a combined $1.14B — up 59% from $717M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new SLDB positions and 26 closed out — a net gain of 10 holders — while 60 added to existing stakes and 39 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $29.5M. The largest seller was Vestal Point Capital, cutting an estimated $21.5M.
- 156 institutional investors held Solid Biosciences (SLDB) as of Q2 2026, up from 150 in Q1 2026.
- Funds reported $1.14B of Solid Biosciences stock for Q2 2026, up 59% quarter-over-quarter.
- 36 funds opened new Solid Biosciences positions in Q2 2026 and 26 closed out, a net change of +10 holders.
- The largest Solid Biosciences buyer in Q2 2026 was RTW Investments, an estimated $29.5M added.
- The largest Solid Biosciences seller in Q2 2026 was Vestal Point Capital, an estimated $21.5M sold.
Based on aggregated 13F filings for Q2 2026.